石四藥集團(02005.HK)2023年淨利潤增17.4%至13.19億港元 末期息每股0.1港元
格隆匯3月27日丨石四藥集團(02005.HK)公佈年度業績,截至2023年12月31日止年度,全年實現銷售收入以人民幣計約58.24億元,同比增長約4.9%,但由於人民幣兑港元較去年平均貶值約4.3%,以港元計,全年銷售收入約64.63億港元,同比增長約0.5%,同期毛利率56.0%,同比上升0.6個百分點;實現淨利潤約13.19億港元,同比增長約17.4%。擬派發末期息0.10港元/股。
集團銷售主要於中國進行並以人民幣計值,截至2023年12月31日止年度換算為港元時平均較去年貶值約4.3%。然而,受惠於靜脈輸液業務及口服制劑業務的增長,按港元計,集團截至2023年12月31日止年度的收益增加至64.63億港元,同比增長0.5%。當中,靜脈輸液的收益為40.41億港元,同比增長15.1%,主要由於銷量增長。其中非PVC軟袋輸液及直立式軟袋的收益分別為20.95億港元及8.81億港元,合共29.75億港元,佔靜脈輸液的總收益73.6%,較去年增加22.1%;PP塑瓶輸液的收益為8.27億港元,佔靜脈輸液的總收益20.5%,較去年減少1.5%;玻璃瓶輸液的收益為2.38億港元,佔靜脈輸液的總收益5.9%,較去年增加1.7%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.